2,054
Views
0
CrossRef citations to date
0
Altmetric
Articles

Cost per responder for guselkumab versus secukinumab in the United States based on a head-to-head trial of moderate to severe plaque psoriasis

&
Pages 518-524 | Received 10 Apr 2020, Accepted 13 May 2020, Published online: 04 Jun 2020